Table of Contents

[Specific Aim 1 3](#_Toc17059163)

[Rationale and Background 3](#_Toc17059164)

[Murine Placental Development and Physiology 3](#_Toc17059165)

[Figure 1: Diagram representing the mouse placental cell types and zones from (Bronson & Bale, 2016) 4](#_Toc17059166)

[Cortisol/Corticosterone Levels in Pregnancy 4](#_Toc17059167)

[Fetal HPA Axis Development 4](#_Toc17059168)

[Glucocorticoid Treatments in Pregnancy 5](#_Toc17059169)

[Effects of Glucocorticoid Exposure on Placental and Fetal Development 5](#_Toc17059170)

[Effect of Glucocorticoid Exposure on Placental Nutrient Transporters 5](#_Toc17059171)

[Glucose Transporters 6](#_Toc17059172)

[Amino Acid Transporters 6](#_Toc17059173)

[Fatty Acid Transport 8](#_Toc17059174)

[Effect of Glucocorticoid Exposure on Placental mTORC1 Function 8](#_Toc17059175)

[Effect of Glucocorticoid Exposure on Placental Endocrine Function 8](#_Toc17059176)

[Effect of In Utero Glucocorticoid Exposure on Offspring 9](#_Toc17059177)

[Experimental Design 10](#_Toc17059178)

[Figure 2: Diagram representing the experimental design and respective timeline 12](#_Toc17059179)

[Figure 3: Diagram representing the breeding method to generate the knockout placenta 13](#_Toc17059180)

[Methods 14](#_Toc17059181)

[Dexamethasone Exposure 14](#_Toc17059182)

[Food Intake 14](#_Toc17059183)

[Body Composition 14](#_Toc17059184)

[Sacrifice and Tissue Collection 14](#_Toc17059185)

[Insulin Tolerance Test 15](#_Toc17059186)

[Real time qPCR 15](#_Toc17059187)

[RNAseq 15](#_Toc17059188)

[Genotyping 15](#_Toc17059189)

[Western Blotting 15](#_Toc17059190)

[Histology 16](#_Toc17059191)

[Expected Results 16](#_Toc17059192)

[Aim 1.1: How does maternal GC exposure affect placental development, fetal growth, and fetal survival? 16](#_Toc17059193)

[Aim 1.2: How does maternal GC exposure affect the expression of placental nutrient transporters? 16](#_Toc17059194)

[Aim 1.3: Is placental mTORC1 signaling altered after maternal GC exposure? 17](#_Toc17059195)

[Aim 1.4: How does maternal GC exposure affect placental endocrine function? 17](#_Toc17059196)

[Aim 1.5: Is offspring survival, weight, body composition and insulin sensitivity altered with maternal GC exposure? 17](#_Toc17059197)

[Aim 1.6: Does a placental GR-KO model rescue the placental and fetal effects of GC exposure? 18](#_Toc17059198)

[Potential Pitfalls and Alternate Approaches (Aims 1.1-1.6) 18](#_Toc17059199)

[Appendix A: Summary Table of Compiled Studies Examining Effects of Antenatal GC on Placental/Fetal Development and Health 19](#_Toc17059200)

# Specific Aim 1

**Determining the effects of glucocorticoid-induced stress on placental** **transport of nutrients and endocrine function.**

The placenta is the direct and only site of communication between mother and fetus during *in utero* development (Brett *et al.*, 2014). The placenta is the rate-limiting step for fetal nutrient and gas acquisition (Brett *et al.*, 2014). Additionally, the placenta plays an important endocrine role to promote fetal growth and nutrient supply (Malassine *et al.*, 2003). The placenta is highly regulated to ensure adequate growth of the fetus in normal pregnancies (Napso *et al.*, 2018). In cases of maternal glucocorticoid-induced stress, placental nutrient transport and endocrine function are compromised leading to potentially suboptimal fetal growth (Kipmen-Korgun *et al.*, 2012; Waffarn & Davis, 2012). In Denmark, 20% of women reported use of corticosteroids from 4 weeks prior to delivery until delivery between 1996-2008 (Hviid & Mølgaard-Nielsen, 2011). The mechanisms by which maternal corticosteroids influence fetal health and placental function are understudied (Kemp *et al.*, 2015). Some side effects like reduced birthweight, offspring hypertension, mental illness and higher childhood HPA axis activity remain controversial (Alexander *et al.*, 2012; Waffarn & Davis, 2012; Duthie & Reynolds, 2013; Reynolds, 2013; Braun *et al.*, 2013; Moisiadis & Matthews, 2014). My hypothesis is that glucocorticoid treatments prior to conception and/or during conception cause altered placental transport and hormonal function in a time-dependent manner by which an early and prolonged exposure during pregnancy has more prominent side effects on the placenta, fetus, and offspring. To test this hypothesis, I will examine a) how maternal dexamethasone affects placental development and function, b) how maternal dexamethasone affects fetal and offspring development and health, and c) the role of placental glucocorticoid receptor (GR) in mitigating the effects of maternal dexamethasone exposure.

# Rationale and Background

## Murine Placental Development and Physiology

The definitive structure of the mouse placenta is (Malassine *et al.*, 2003). The placenta encompasses two sides, an arc-shaped surface facing the maternal side and another flat surface facing the fetal side (Georgiades *et al.*, 2002). The mouse placenta has three distinct compartments, a decidual maternal zone which is the outermost compartment, a fetal-derived junctional zone that mediates placental endocrine function, and a fetal-derived labyrinth zone that comprises the majority of the placenta and is the main site for nutrient and gas exchange (Woods *et al.*, 2018). Three exchange barriers exist moving inwards from the decidua to the fetal compartment including two syncytiotrophoblast layers (in the labyrinth layer) and one fetal endothelial cell layer (Georgiades *et al.*, 2002). The two syncytiotrophoblast barriers comprise the microvillous membrane facing the maternal circulation and the basal membrane facing fetal circulation (Brett *et al.*, 2014). Figure 1 represents the mouse placenta (Bronson & Bale, 2016).

At midgestation, placental invasion of the maternal uterine cavity occurs to allow maternal blood flow into the placental cavity (Malassine *et al.*, 2003; Woods *et al.*, 2018). This invasion permits direct nutrient uptake from the maternal circulation to the fetus through the placenta. Prior to this invasion, the embryo acquires nutrients from the yolk sac, the initial placental structure that absorbs nutrients from maternal circulation (Malassine *et al.*, 2003; Woods *et al.*, 2018).

### Figure 1: Diagram representing the mouse placental cell types and zones from (Bronson & Bale, 2016)



*Neuropsychopharmacology Reviews* (2016) **41**, 207-218;

doi:10.1038/npp.2015.231

## Cortisol/Corticosterone Levels in Pregnancy

During human pregnancy, mean cortisol rises gradually as pregnancy progresses (Carr *et al.*, 1981). Mean cortisol levels increase in humans during the first, second and third trimester by 1.6, 2.4 and 2.9 folds, respectively (Jung *et al.*, 2011). The increased cortisol levels may be explained by placental secretions of estrogen stimulating maternal cortisol production and mitigating maternal negative feedback (Lindsay & Nieman, 2005; Duthie & Reynolds, 2013) and/or by placental production of corticotropin-releasing hormone (CRH) into the maternal circulation in mid- and late gestation (Duthie & Reynolds, 2013). Maternal cortisol promotes placental CRH production, which in turn promotes maternal HPA axis activity thus acting as a feed-forward positive mechanism.

However, in mouse pregnancy, corticosterone levels do not increase as much as humans near term although there are still increases. In pregnant control mice, corticosterone levels were not significantly different at E11 and E17 despite slightly higher levels at E17 (Jafari *et al.*, 2017). Other studies showed an increase in corticosterone levels at E19 compared to E16 in control unstressed mice (Vaughan *et al.*, 2012). Unstressed pregnant mice had higher corticosterone levels with peak levels at E16 being 60 times higher than non-pregnant mice (Barlow *et al.*, 1973). The levels then dropped after E16 until delivery at E19 (Barlow *et al.*, 1973).

## Fetal HPA Axis Development

The human fetal hypothalamic-pituitary axis activity is detected as early as 8-12 weeks of gestation (Ng, 2000) and is fully developed in the second trimester of pregnancy (Moisiadis & Matthews, 2014). In early pregnancy, fetal cortisol is thought to primarily be attained from maternal cortisol, as the fetus is believed to sufficiently produce cortisol at 22 weeks of gestation (Buss *et al.*, 2012). Given the critical developmental window by which fetal organs and HPA axis are developing, it is possible that increased maternal cortisol levels in early pregnancy compared to late pregnancy may have more deleterious effects on fetal development (Barker, 2007; Braun *et al.*, 2013). In mice, the offspring HPA develops postnatal in two phases. On postnatal day (PND) 1 through 12, the mouse HPA is considered hypo-responsive, and after PND 12 the HPA system matures (Schmidt *et al.*, 2003).

## Glucocorticoid Treatments in Pregnancy

In addition to the naturally increasing cortisol levels in pregnancy, glucocorticoid (GC) treatments are further prescribed during pregnancy for multiple reasons. A single course of synthetic corticosteroid treatment is prescribed to women who are at risk of delivering premature babies. The treatment is proven to increase offspring chances of survival post-delivery (Doyle *et al.*, 2000; Baisden *et al.*, 2007). Glucocorticoid treatments are prescribed as they enhance fetal growth, specifically fetal lung maturation to prevent respiratory distress syndrome (RDS), and aid in overall embryogenesis to prevent perinatal death due to hemorrhages, heart failure and other underlying causes associated with preterm birth (Lunghi *et al.*, 2010; Singh *et al.*, 2012). Specifically, betamethasone, dexamethasone, prednisolone, corticosteroids, or cortisol are prescribed to women who have acute asthma or asthma, hyperemesis gravidarum, depression, stress, or are at risk of delivering preterm babies (Singh *et al.*, 2012). The use of corticosteroids is widespread. In a Danish cohort study encompassing all births in Denmark from 1996-2008, about 20% of women reported use of corticosteroids from 4 weeks prior to delivery until delivery (Hviid & Mølgaard-Nielsen, 2011). In an American cohort study including 152,531 pregnancies between 1996-2000, 3.5% of pregnant women who had a documented diagnosis associated with preterm birth used corticosteroids, while 1.7% of pregnant women who did not have a documented diagnosis used corticosteroid (Andrade *et al.*, 2004). Despite the placenta’s function to protect the fetus from excess maternal corticosteroid, synthetic corticosteroids used in preterm treatments can readily cross the placenta bypassing inactivation by HSD11B2(Cuffe *et al.*, 2011; Singh *et al.*, 2012).

## Effects of Glucocorticoid Exposure on Placental and Fetal Development

Pregnant rats treated with dexamethasone at E13 until E20 showed reduced placental and fetal weights (Ain *et al.*, 2005). Despite the evident placental and fetal growth restriction, dexamethasone did not affect litter size or fetal viability (Ain *et al.*, 2005). Rats exposed to triamcinolone once at E16 had 53% reduction in placental weight and 73% reduction in fetal weights (Hahn *et al.*, 1999). Mice exposed to a sound stressor on E10.5, E12.5, and E14.5 showed reduced fetal body weight and had growth restriction that was more evident in female fetuses (Wieczorek *et al.*, 2019). Pregnant mice exposed to dexamethasone on E15, E16, and E17 had reduced placental and fetal weights and trophoblast swelling in the junctional and labyrinth zones (Baisden *et al.*, 2007). Furthermore, mice given dexamethasone at E11-E16 had reduced fetal and placental weights at E16, but the volume of the placental junctional and labyrinth zone was unchanged despite less fetal capillaries in the labyrinth zone (Vaughan *et al.*, 2012). On the contrary to the evident reduction in placental and fetal weights seen in some papers, mice treated with dexamethasone on E13.5 and E14.5 showed no effect on fetal weight at E15.5, E18.5, or at birth (Audette *et al.*, 2011). There was also no effect on placental weights at E15.5, E17.5 in male or female placentas, but at E18.5 female placentas had reduced weight but male placentas were not different (Audette *et al.*, 2011). However, placental junctional and labyrinth zone proportions with respect to the total placental area was unchanged (Audette *et al.*, 2011).

## Effect of Glucocorticoid Exposure on Placental Nutrient Transporters

Since the placenta is the only source of fetal nutrient acquisition, transporter expression may reflect the efficiency at which maternal nutrients pass through the placenta to the fetus. To pass to the fetus, the nutrients need to bypass the three placental exchange barriers including two syncytiotrophoblast layers and the fetal endothelial cell layer (Georgiades *et al.*, 2002). The findings below highlight the conflicting evidence within species and between models regarding placental transporter expression, which emphasizes the need for further studies.

### Glucose Transporters

Glucose transport across the mammalian placenta is thought to occur mainly via GLUT1 and is complemented by GLUT3 (Hahn & Desoye, 1996; Hahn *et al.*, 1999). GLUT1 and GLUT3 are the most extensively studied transporters in the placenta. Rats exposed to triamcinolone (TA) at E16 had reduced mRNA and protein expression of GLUT1 and GLUT3 at E21 (Hahn *et al.*, 1999). Inversely, pregnant rats exposed to 100 or 200 ug/kg body weight/ day of dexamethasone starting at E15 showed increased placental GLUT1 protein expression by 1.6 and 1.9 fold, respectively at E21 indicating a dose-dependent effect (Langdown & Sugden, 2001).

Mice exposed to corticosterone in their drinking water at E11-E16 had increased placental GLUT1 and GLUT3 gene expression at E16, while mice exposed at E14-E19 showed unchanged expression (Vaughan *et al.*, 2015). Unlike the transporter expression at both timepoints, transplacental clearance of radiolabeled glucose was unchanged at E16 after the exposure from E11-E16, but clearance was reduced by 33% at E19 after exposure from E14-E19 (Vaughan *et al.*, 2015). This suggests that other glucose transporters may be involved in placental glucose uptake (Vaughan *et al.*, 2015). Opposite results show that mice treated with dexamethasone for 60 hours via a minipump starting at E12.5 showed unaltered gene expression of GLUT1 and GLUT3 at E14.5 and at E17.5 (Cuffe *et al.*, 2011).

Human placental extracts from term deliveries further showed reductions in GLUT1 mRNA and protein expression after TA treatment along with reduced protein expression of GLUT3 but unaltered GLUT3 mRNA expression (Hahn *et al.*, 1999). Another study showed that human placental extracts from term deliveries had unaltered GLUT1 mRNA expression but increased GLUT1 protein expression when treated with 1, 2, and 20 mg/ml of hydrocortisone (Mateos *et al.*, 2018). GLUT3 mRNA expression was increased when placental explants were treated with 2mg/ml hydrocortisone only (Mateos *et al.*, 2018). Despite the increased GLUT3 mRNA expression at 2mg/ml and the increased GLUT1 protein expression at all doses of hydrocortisone, placental uptake of radiolabeled glucose was decreased by 30-40% when explants were treated with 2 and 20 mg/ml hydrocortisone (Mateos *et al.*, 2018).

Refer to *Appendix A* for a table summary of results.

### Amino Acid Transporters

Amino acid concentrations are higher in the fetal umbilical vein than in the mother’s circulation showing a need for active transport of amino acids through the placenta (Cetin *et al.*, 1996). Several transport systems exist on the placental membrane including System A for alanine, serine, proline, and other neutral amino acids, System ASC for alanine, serine and cysteine, and anionic amino acids, System L for leucine, isoleucine, valine, tyrosine, and other neutral amino acids, System N, for neutral and cationic amino acids, system β, system y+, and other systems (Regnault *et al.*, 2002; Gaccioli *et al.*, 2015; Vaughan *et al.*, 2017). System A is sodium-dependent and allows transport of small non-branched amino acids like alanine and glycine (Jones *et al.*, 2006), and its activity is strongly related to fetal growth with evidence suggesting that system A activity being negatively associated with the severity of IUGR (Glazier *et al.*, 1997; Vaughan *et al.*, 2017). Hence, despite the presence of multiple placental amino acid transport systems, system A was the main studied system in most of the currently available research.

Midgestation administration of dexamethasone in mice at E13.5 and E14.5 caused unaltered placental System A transfer of radiolabeled amino acid at E15.5 and E17.5 along with unchanged mRNA expression of SNAT1, SNAT2 and SNAT4 in male and female placentas (Audette *et al.*, 2011). However, at E18.5, system A mediated amino acid transfer of radiolabeled amino acid was reduced in male and female placentas despite no significant changes in SNAT1, SNAT2, and SNAT4 transporter expression at E18.5 (Audette *et al.*, 2011). This indicates a potential long-term effect of midgestational dexamethasone exposure on placental system A amino acid transfer (Audette *et al.*, 2011). Furthermore, at E16, mice treated with dexamethasone in their drinking water at E11-E16 showed unchanged fetal accumulation of radiolabeled amino acid despite a 35% increase in placental radiolabeled amino acid accumulation and increased SNAT1 and SNAT2 gene expression but unaltered SNAT4 expression (Vaughan *et al.*, 2012). At E19, mice given dexamethasone at E14-E19 had reduced fetal and placental accumulation of radiolabeled amino acid by 40-50% despite showing increased SNAT1 expression with unchanged SNAT 2 and SNAT4 expression (Vaughan *et al.*, 2012). Mouse placentas at E19 from those given dexamethasone at E11-E16 had a 38% increase in fetal accumulation of amino acid despite no change in placental accumulation and no change in SNAT1, SNAT2, and SNAT4 expression (Vaughan *et al.*, 2012). This further indicates a time-dependent effect on amino acid transporter expression, placental transport, and fetal accumulation. No change in gene expression of SNAT1, SNAT2, and SNAT4 at E14.5 and at E17.5 was detected in mice given dexamethasone for 60 hours starting at E12.5 (Cuffe *et al.*, 2011).

Human placental explants from term pregnancies were incubated with dexamethasone for 48 hours showed 30% increase in placental uptake of radiolabeled amino acid at 10-6 M but not at 10-8 M despite no changes in mRNA expression of SNAT1, SNAT2 or SNAT4 at both concentrations (Audette *et al.*, 2010). Human term placental extracts from women who were treated with glucocorticoids during gestation showed varied effects depending on the intermittent time between the treatment and delivery (Audette *et al.*, 2014). Uptake of radiolabeled amino acid by placentas of mothers who delivered 14 days after the GC treatment but prior to term was lower than uptake from delivered placentas within less than 14 days of treatment (Audette *et al.*, 2014). Compared to term controls of untreated mothers, term placentas from GC treated mothers had significantly lower system A transport (Audette *et al.*, 2014). Gene expression revealed no effect on SNAT1 and SNAT2 across all treatment groups and the control, but GC-treated term placentas had reduced SNAT4 expression compared to GC-treated placentas delivered after 14 days of treatment but prior to term (Audette *et al.*, 2014). This further suggests that long-term effects of dexamethasone may be more critical given that the reduced transport was amplified in GC-treated placentas delivered after 14 days of treatment but prior to term and in GC-treated term placentas compared to placentas delivered within 14 days of treatment (Audette *et al.*, 2014).

In humans, system A transport of radiolabeled amino acids was significantly lower in placental explants of IUGR deliveries (Shibata *et al.*, 2008). Additionally, placental uptake of lysine was reduced at the basolateral membrane, while system-L-mediated uptake of leucine was reduced in the microvillous and basal membranes of placental explants from IUGR pregnancies (Jansson *et al.*, 1998). IUGR placentas had 34% lower sodium-dependent taurine transport in the microvillous membrane compared to healthy controls (Norberg *et al.*, 1998).

BeWo choriocarcinoma human placental cell lines showed higher radiolabeled sodium-dependent amino acid transfer between membranes when incubated with 1000nM cortisol (Jones *et al.*, 2006). SNAT1 mRNA expression was unchanged when BeWo cells were incubated with cortisol at 20, 50, 1000, and 2500 nM, but SNAT2 mRNA expression increased by 21% and 30% when incubated with cortisol at 1000nM and 2500nM (Jones *et al.*, 2006). SNAT2 protein expression further showed an 11% increase with 1000nM cortisol (Jones *et al.*, 2006).

Refer to *Appendix A* for a table summary of results.

### Fatty Acid Transport

Lipoprotein lipase (LPL) is present on the placental microvillous membrane and plays a crucial role in lipid metabolism (Huter *et al.*, 1997). Its activity comprises the first step of placental transfer of fatty acids from mother to fetus by breaking down maternal triglycerides into fatty acids that can then be transported across the placenta (Huter *et al.*, 1997). Low-density lipoprotein (LDL) receptor is also located on the microvillous membrane of the placenta and is important for uptake of LDL from the maternal circulation to the fetus through the placenta (Huter *et al.*, 1997).

To my knowledge, lipid transporter expression and transport activity have not been assessed after antenatal GC exposure, but one study did assess lipoprotein lipase activity along with fatty acid esterification and oxidation (Mateos *et al.*, 2018).Using placental explants from term deliveries, fatty acid utilization and storage was altered when cells were treated with hydrocortisone. Fatty acid oxidation was reduced by 25, 50 and 75% in explants treated with 1, 2 and 20 mg/ml hydrocortisone (Mateos *et al.*, 2018). Fatty acid esterification was also reduced at all doses used. Lipoprotein lipase (LPL) activity showed reductions by 40 and 80% when cells were incubated with 2 and 20 mg/ml hydrocortisone (Mateos *et al.*, 2018). Hence, fatty acid uptake, storage and oxidation were all impaired. This same study showed reductions in radiolabeled glucose uptake at 2 and 20 mg/ml doses, and the reduced fatty acid metabolism capacity further suggests failed placental compensatory mechanism to utilize fatty acids when glucose uptake is compromised, despite the availability of nutrients (Mateos *et al.*, 2018).

In humans, microvillous membrane LPL activity was reduced by 47% in placentas of IUGR preterm pregnancies (Magnusson *et al.*, 2004). Additionally, LDL receptor protein levels were reduced in placentas from pregnancies with IUGR (Wadsack et al., 2007).

Finally, ultrasound images of human growth-restricted fetuses showed reduced fat and lean mass, suggesting fetal nutrient deprivation (Padoan *et al.*, 2004).

Refer to *Appendix A* for a table summary of results.

## Effect of Glucocorticoid Exposure on Placental mTORC1 Function

mTORC1 is a crucial nutrient sensor that plays a role in integrating maternal and fetal signals to ensure adequate nutrient transport to the fetus through the placenta (Wen *et al.*, 2005; Roos *et al.*, 2007; Mparmpakas *et al.*, 2012; Jansson & Powell, 2013). Fewer studies have assessed the relationship between maternal GC exposure and placental mTORC1 activity in rodents or humans, but its activity is reduced in intrauterine growth restriction (Roos *et al.*, 2007). Mice exposed to corticosterone at E14-E19 had reduced mTORC1 activity at E19 evident by the reduced p4E-BP1 and pS6K expression, downstream targets of mTORC1, and increased REDD1 expression which is an inhibitor of mTORC1 signaling (Vaughan *et al.*, 2015). Mice exposed to corticosterone at E11-E16 had reduced pAKT levels but unchanged total AKT levels and unchanged REDD1 expression, suggesting a minimal effect on mTORC1 function at E16 (Vaughan *et al.*, 2015).

## Effect of Glucocorticoid Exposure on Placental Endocrine Function

Pregnant rats treated with dexamethasone at E13 had reduced *Igf2* mRNA expression in the junctional zone but unaltered expression in the labyrinth zone (Ain *et al.*, 2005). Conversely, pregnant mice exposed to glucocorticoids at midgestation showed no change in placental *Igf2* gene expression (Baisden *et al.*, 2007; Cuffe *et al.*, 2011; Vaughan *et al.*, 2015).

Growth differentiation factor 15 is produced in the placenta, and changes are associated with a variety of complications including miscarriage, nausea and hypertension (Tong *et al.*, 2004; Chen *et al.*, 2016; Petry *et al.*, 2018). There are no studies assessing placental GDF15 activity in response to GC or psychological stress exposures. Placental GDF15 levels are positively correlated with maternal and fetal GDF15 levels, suggesting that the placenta is the primary source of this hormone during pregnancy (Sugulle *et al.*, 2009). Based on our results, other placental hormones may be assessed in the future.

## Effect of In Utero Glucocorticoid Exposure on Offspring

Women with higher corticotropin-releasing hormone at midgestation, were 7.5 fold more likely to deliver preterm (Inder *et al.*, 2001). However, offspring outcome remains conflicting. In humans, antenatal corticosteroid exposure caused higher systolic and diastolic blood pressure in children ages 14 years (Doyle *et al.*, 2000). At 30 years of age, offspring of mothers who received antenatal betamethasone had higher insulin levels 30 minutes after a glucose tolerance test with lower glucose concentrations at 120 minutes, but offspring did not have altered cortisol levels, lipid profile or blood pressure (Dalziel *et al.*, 2005). This suggests an impaired insulin sensitivity (Dalziel *et al.*, 2005). Additionally, body composition of children of mothers who had higher cortisol levels during pregnancy showed increased fat mass index in girls but a lower fat mass index in boys indicating a sex-difference (Van Dijk *et al.*, 2012). Maternal third trimester cortisol levels were positively associated with infant body fat percent increase from age 1-6 month suggesting programmed adiposity that can contribute to childhood obesity (Entringer *et al.*, 2016). Antenatal GC treatment showed a blunted HPA axis activity in infants ages 3-6 days after a stressful exposure (Davis *et al.*, 2004). Despite showing reduced cortisol levels in newborns exposed to antenatal glucocorticoids, long-term effects vary. Children ages 6-11 years who were exposed to antenatal glucocorticoids had higher cortisol levels in response after a standardized stressful test, and this difference was mainly influenced by higher salivary cortisol in females, indicating a potential sex-dependent elevation in HPA axis activity effect (Alexander *et al.*, 2012). Studies have shown multiple offspring outcomes including increased blood pressure in children, increased risk of preeclampsia, impaired mental development in infants, increased infant cortisol, reduced fetal weight, and other symptoms associated with timing, dosage and type of corticosteroid treatment during pregnancy (Singh *et al.*, 2012).

In mice, male offspring exposed to dexamethasone for 60 hours starting at E12.5 had lower fetal weights at E14.5 but not at E17.5 (O’Sullivan *et al.*, 2013). The male offspring from similarly treated dams had similar weights at 2 weeks, 4 weeks, and 3 and 6 months of age (O’Sullivan *et al.*, 2013). Twenty-one-day-old rats exposed to antenatal dexamethasone at E15 till delivery had 66% lower body weights than controls, lower corticotropin releasing hormone content and concentrations, lower adrenal and plasma corticosterone levels and severe adrenal atrophy (Dupouy *et al.*, 1987). Conversely, rats exposed to antenatal glucocorticoids showed unaltered ACTH and corticosterone plasma levels at PND1,7,9, and 20 but had a suggested increased HPA axis activity when stress was induced during adulthood (Bakker *et al.*, 1995). Offspring of physically stressed rats during gestation showed higher plasma glucose levels at 24 months of age despite similar insulin secretion when challenged with oral glucose tolerance test (Lesage *et al.*, 2004).

# Experimental Design

To determine how glucocorticoid exposure affects placental function, we will obtain a total of 80 female and 80 male mice (n=10 females and 10 males per group- 8 groups total)[[1]](#footnote-2) that are 8 week-old C57BL/6 virgin mice from Jackson laboratory. Mice will be given two weeks to acclimatize with *ad libitum* access to normal chow diet and water. After acclimatization, mice will then be single-housed and randomized into one of the following groups, to assess placental morphology (at E14.5) and effects on offspring (at delivery). The experimental design is represented in Figure 2. Pending these results other groups may be evaluated at different gestation timepoints.

Cohort A of groups treated one week prior to gestation:

1. *Water Pre-gestation till E14.5:* control group on water one week prior to conception and until midgestation at embryonic day 14.5
2. *Dexamethasone Pre-gestation till E14.5*: experimental group exposed to dexamethasone in drinking water a week prior to conception and until midgestation at embryonic day 14.5
3. *Water Pre-gestation till Delivery*: control group on water one week prior to conception and until delivery
4. *Dexamethasone Pre-gestation till Delivery*: experimental group exposed to dexamethasone in drinking water a week prior to conception and until delivery

Cohort B of groups treated at conception:

1. *Water Conception till E14.5*: control group on water starting at conception and until midgestation at embryonic day 14.5
2. *Dexamethasone Conception till E14.5*: experimental group exposed to dexamethasone in drinking water starting at conception and until midgestation at embryonic day 14.5
3. *Water Conception till Delivery*: control group on water starting at conception and until delivery
4. *Dexamethasone Conception till Delivery*: experimental group exposed to dexamethasone in drinking water starting at conception and until delivery

All groups will have *ad libitum* access to normal chow diet and water or dexamethasone depending on treatment arm. Experimental groups will receive 1mg/kg/day dexamethasone in their drinking water with *ad libitum* access. For groups of Cohort A (receiving dex or water a week prior to conception), female mice will be mated with age-matched male mice after one week of treatment. A copulatory plug will be checked daily to identify E0.5 day. For groups of Cohort B (receiving dex or Water at conception), mice will be mated with age-matched males immediately after acclimatization while having *ad libitum* access to water. We will check for the presence of copulatory plugs daily to determine treatment initiation. Once a copulatory plug is identified, mice will be placed on dexamethasone or water based on their assigned group.

Males will be removed from the cage after a copulatory plug is detected to minimize male exposure to treatment and to better detect potential miscarriages. Dams from all groups will undergo body mass assessment three times weekly using magnetic resonance to assess body composition. Water and food intake will be recorded weekly. For groups that will be sacrificed prior to delivery (E14.5), placental and fetal extractions will occur midgestation at E14.5, since by midgestation, the placenta is fully developed and mature. Briefly, the dams will be anesthetized using a vaporizer during the placental and fetal extraction. Litter size will be determined per dam and will account for potential resorbed placentas. Placental and fetal weights will be collected. Placentas will be snap frozen in liquid nitrogen while some will be embedded in paraffin for histology. Molecular studies on placental samples will be conducted to determine protein expression.

For the groups that will deliver their pups at E21.5, survival and birth rates will be noted. Water and dex groups that will complete their pregnancy and deliver their pups will have *ad libitum* access to normal chow diet and will be placed on regular water immediately after parturition and during lactation (no dex exposure during lactation). Pups will be sexed and culled to 2 at PND2.5. The offspring will be weighed at PND0.5, PND7.5, 14.5, and at 21.5. Pups will be weaned based on sex and treatment group. The weaned pups will have *ad libitum* access to normal chow diet and water. Their water and food intake will be assessed weekly. They will further undergo body composition analysis by echoMRI at weaning and weekly thereafter till 6 weeks of age. At the age of 6 weeks, offspring insulin sensitivity will be assessed by an insulin tolerance test (ITT) followed by sacrifice and tissue collection of fat pads 3 days after the ITT. Offspring fat pads (gWAT and iWAT) will be collected and weighed to determine adiposity.

To determine if the effects of dexamethasone exposure on the placenta and the fetus can be rescued, we will develop a placenta-specific glucocorticoid receptor knockout (KO) model. To isolate placental from fetal and maternal glucocorticoid signaling, our knockout model will ablate GR conditionally in the placenta. To my knowledge, this is the first time such a model has been generated. To generate the GR-KO, we will use the Cre-loxP recombination technology. We will leverage the fact that placental tissue is primarily fetal derived, so the genotype of the offspring will dictate the genotype of most of the placenta. The breeding scheme is represented in Figure 3. First, female mice with homozygously flanked exon 2 of *Nr3c1* will be crossed with a male having placental driver *Cyp19a1-CreTg/+* (Wenzel & Leone, 2007).This *Cyp19a1-Cre* has been also used elsewhere to generate a placental knockout model (Wieczorek *et al.*, 2019). This cross will generate wild-type (WT) and heterozygous (Het) offspring at a 1:1 ratio. The expected timeline between this first breed and the second one is 9-12 weeks. The offspring of this first cross will be bred (WT x Het) to generate the parental strains for this experiment. Briefly, this cross will yield a combination of knockout *Nr3c1* fl/fl;*Cyp19a1-CreTg/ +*, conditionally heterozygous *Nr3c1* fl/+;*Cyp19a1-CreTg/+* , and wild-type *Nr3c1* fl/fl ; *Cyp19a1-Cre* +/+ , *Nr3c1* fl/+ ; *Cyp19a1-Cre* +/+ , *Nr3c1* +/+ ; *Cyp19a1-Cre* +/+ , or *Nr3c1* fl/fl ; *Cyp19a1-Cre* Tg/+ (no Cre transgene) at an expected ratio of 1:2:5 with the knockout and wild-type (*Nr3c1* fl/fl ; *Cyp19a1-Cre* +/+ only) animals only being used for further breeding. The expected timeline for this second cross to generate mature offspring capable of breeding is also 9-12 months. The final parental breed of WT x KO will generate our placental KO model. The final offspring generated from the next generation will all have the floxed allele with the Cre (KO) or without (WT). The offspring generated from the last main parental breed will either be WT with intact placentas or knockout with placental KO and a phenotypically WT embryo.

The dams with GR-KO will be treated with dexamethasone similar to the previous groups in cohorts A and B to determine placental, embryonic and offspring function and growth.

### Figure 2: Diagram representing the experimental design and respective timeline



### Figure 3: Diagram representing the breeding method to generate the knockout placenta



# Methods

## Dexamethasone Exposure

Water-soluble dexamethasone (Sigma) will be prepared at a concentration of 53 mg/L, which our previous work shown results in a dose of approximately 1 mg/kg/day in non-pregnant mice.

If the dam is single housed or nursing pups:

(the new added total water/dexamethasone- the last measurement’s water/dexamethasone) / # of days between measurements

If more than one adult mouse is in the cage (when the male is breeding in the same cage), food intake will be calculated as follows:

(the new added total water/dexamethasone - the last measurement’s water/dexamethasone) \* #of days between measurements / sum of days spent by each mouse in that cage between measurements

## Food Intake

Food will be weighed when the treatment starts and throughout the experiment. The weight of the dam’s food will be recorded three times weekly every Monday, Wednesday, and Friday. Food will also be weighed at delivery for the dam. Food will be topped off to ~400g weekly every Friday. Food intake will be calculated as:

If the dam is single housed or with nursing pups:

(the new added total food weight - the last measurement’s food weight) / # of days between measurements

If more than one adult mouse is in the cage (when the male is breeding in the same cage, or when weaned offspring are housed together), food intake will be calculated as follows:

(the new added total food weight - the last measurement’s food weight) \* #of days between measurements / sum of days spent by each mouse in that cage between measurements

## Body Composition

Mice will be weighed by using dynamic weighing to capture accurate weight using a digital scale. The weight will be recorded along with the mouse ear tag number. The mouse will be gently placed in the MRI tube with the plunger slightly compressing along the mouse body to ensure it cannot move during the measurement. Fat, lean, free water and total water mass (g) will be recorded for each animal.

## Sacrifice and Tissue Collection

Dams of groups E14.5 will be sacrificed on the respective dates based on their treatment group. Dams will be anesthetized using an isoflurane vaporizer. Toe punches will be performed to ensure that the mouse is under anesthesia. A midline incision of the skin from the rectum to the diaphragm will be made while the mouse is still alive and anesthetized using the vaporizer. The uterine horn will be exposed and placental and fetal excision will begin in order along the uterine horn starting from the side (closer to the ovaries). The amniotic sac for each pup will be ruptured using fine scissors. The placenta will be detached from the maternal tissue and the umbilical cord then weighed and immediately snap frozen or cryopreserved and in paraffin for future molecular and histological studies. Fetuses will be weighed after removal from the amniotic sac then they will be immediately sacrificed by decapitation using surgical scissors. After the complete extraction of tissue, dams will be euthanized while under anesthesia by cardiac exsanguination.

Offspring of dams that will be allowed to deliver and nurse (groups of E21.5) will be dissected at 6 weeks of age. Offspring will be first anesthetized using isoflurane drop jar. Offspring will be sacrificed using isoflurane drop jar. Cervical dislocation will be performed as a secondary measure to confirm euthanasia. We will dissect the offspring fat pads by a midline incision of the skin from the rectum to the diaphragm, extract inguinal and gonadal white adipose tissue. Inguinal white adipose tissue (iWAT) will be collected from the mouse right side first by pulling the peritoneum away from the skin. Inguinal fat will be carefully extracted, weighed then snap frozen in liquid nitrogen for further molecular studies. Right gonadal white fat tissue (gWAT) will be collected next by scraping the fat along the gonads (ovaries or testis), weighed, and then snap frozen in liquid nitrogen in 2ml tubes. The fat pads will be stored at a temperature of -80C.

## Insulin Tolerance Test

Weaned offspring in groups water or dexamethasone till delivery from cohort A (pre-gestation) and cohort B (at conception) will undergo an insulin tolerance test (ITT) being challenged with 1 U/kg body weight after a 6-hour fast with *ad libitum* access to water. The effects of antenatal glucocorticoid exposure on offspring adolescent insulin sensitivity will be determined. Briefly, after the fast, the tail will be cut to allow for blood sampling via AccuCheck Advantage Glucometer. Tail vein blood will be immediately measured at 0minutes after the 6-hour fast to denote fasting blood glucose. Mice will be injected by a syringe into the interperitoneal cavity with the appropriate insulin dosage. The timer will be set as to allow for blood collection every 15 minutes. Blood will be collected at 5, 30, 45, 60, 75, 90 and 120 minutes after injection. After the ITT is done, mice will have *ad libitum* access to normal chow diet and water again. These data will be analyzed by mixed linear models of glucose at each time point.

## Real time qPCR

Using the placental tissues collected from the dams, PCR will be performed for *Sry* to determine the sex of the placentas/fetuses using fetal tails. We will use sequence-specific primers to amplify *Sry* gene. Briefly, the tail will be homogenized and treated to collect the DNA. Sample, forward and reverse *Sry* primers, dNTP, polymerase, sterile water, and manufacturer buffer will be mixed. Thermal cycler will be run at various temperatures for ~4 hours.

## RNAseq

To determine gene expression of placentas exposed to antenatal GC, we will perform RNAseq studies. We will use 5 male and 5 female placentas from each group exposed to water or dexamethasone. RNAseq will be done by the University of Michigan DNA Core. We will align reads to the mouse genome using a TopHat/DESeq/GSEA pipeline to identify differentially expressed placental genes. To determine the enriched core, we will use the genes of interest involved in nutrient transport and endocrine function of the placenta. We will determine if dexamethasone effects on the placenta are sex-dependent. We will use network analysis leveraging TRANSFAC and the Signaling Pathway Project to identify potential transcription factors and pathways at play. Our lab has extensive experience in performing RNAseq studies (Lu *et al.*, 2014; Hochberg *et al.*, 2015; Urraca *et al.*, 2015; Ponnusamy *et al.*, 2017; Ochsner *et al.*, 2019).

## Genotyping

Maternal and fetal genotyping will be conducted to confirm the GR KO or WT genotype of the dams and fetuses/placentas. To genotype the dams, DNA extraction from tail clips will be done. qPCR analysis of the *Nr3c1* gene will be conducted to determine gene expression. For fetal/placental genotyping, fetal tail will be entirely clipped for DNA analysis along with a section of the placenta to confirm expression of *Nr3c1.*

## Western Blotting

Using the placentas collected at E14.5, mTORC1 activity will be assessed. Validation of glucocorticoid receptor ablation will be validated from collected placentas. Briefly, a portion of the sample will be boiled and loaded into different wells with a ladder control. Proteins will transfer to nitrocellulose overnight. The matrix will be stained for total protein using Revert total protein and scanned by LiCOR to normalize against total protein. Samples will be incubated with the primary then the secondary antibodies. Briefly, antibodies against total and phosphorylated mTORC1 targets (S6K, 4EBP1, S6) and regulators (Akt, IRS and TSC2) and antibodies against GR will be used.

## Histology

Placentas collected from control and experimental at E14.5 will be embedded in paraffin and stained at the Rogel Cancer Center’s Tissue and Molecular Pathology. Slides will be blindly assessed for labyrinth thickness and area.

# Expected Results

## **Aim 1.1:**How does maternal GC exposure affect placental development, fetal growth, and fetal survival?

I hypothesize that our prolonged dexamethasone exposure will reduce placental and fetal weights along with reduced placental labyrinth zone area causing intrauterine growth restriction (IUGR) in group of dexamethasone pre-gestation till E14.5 and in the group of dexamethasone conception till E14.5 with more pronounced effect in the groups treated with dexamethasone pre-gestation over groups treated at conception. Pregnant mice exposed to dexamethasone on E15, E16, and E17 had reduced placental and fetal weights and trophoblast swelling in the junctional and labyrinth zones (Baisden *et al.*, 2007). Furthermore, mice given dexamethasone at E11-E16 had reduced fetal and placental weights at E16, but the volume of the placental junctional and labyrinth zone was unchanged despite less fetal capillaries in the labyrinth zone (Vaughan *et al.*, 2012), which suggests that our prolonged exposure will have more drastic effects on placental labyrinth area. To my knowledge, studies assessing effects of glucocorticoid treatment pre-gestation or very early in gestation are lacking. My preliminary data shows that mice treated with 1 mg/kg of the synthetic glucocorticoid dexamethasone in the drinking water from 1 week prior to mating through pregnancy had 1) dramatically reduced fertility whereby litter size from treated dams was 34% lower and had 2) 37% reduction in offspring birth weight. I thus expect fetal survival to be reduced as evident by resorption more so in the dexamethasone pre-gestation group than in the conception group.

## **Aim 1.2:** How does maternal GC exposure affect the expression of placental nutrient transporters?

The experiments conducted in this aim will examine the effect of dexamethasone treatment on placental transport and transporters. I predict that placental glucose transporters, GLUT1 and GLUT3, will have increased gene expression. This is supported by increased placental GLUT1 protein expression at E21 in rats exposed to 100 and 200 ug/kg body weight/ day of dexamethasone starting at E15 (Langdown & Sugden, 2001). Furthermore, mice exposed to corticosterone in their drinking water at E11-E16 had increased placental GLUT1 and GLUT3 gene expression at E16 (Vaughan *et al.*, 2015). This exposure timing (E11-E16) covers our window of interest at E14.5, but it is worthy to note that not all studies detected changes in glucose transporter expression during pregnancy using various exposure windows and doses (Cuffe *et al.*, 2011; Vaughan *et al.*, 2015; Mateos *et al.*, 2018).

Since system A amino acid transport is the most associated with growth restriction (Glazier *et al.*, 1997), which is expected to occur after our exposure (from *Aim* 1), my hypothesis will focus on SNAT1, SNAT2, and SNAT4 expression. I predict increased placental system A amino acid transporter expression of SNAT1, SNAT2 but unchanged SNAT4 with our GC exposures. This hypothesis is supported by increased SNAT1 and SNAT2 gene expression but unaltered SNAT4 expression at E16 in mice treated with dexamethasone in their drinking water at E11-E16, which covers our window of interest at E14.5 (Vaughan *et al.*, 2012). At E19, mice given dexamethasone at E14-E19 also showed increased SNAT1 expression but unchanged SNAT2 and SNAT4 expression (Vaughan *et al.*, 2012). This further indicates a time-dependent effect on amino acid transporter expression, by which our longer exposure starting at pre-gestation or at conception will yield more similar results to the exposure given at E11-E16. It is worth noting that different exposure periods and pregnancy timepoints did not show a change in expression of all the SNAT genes (Jones *et al.*, 2006; Audette *et al.*, 2010, 2011, 2014; Cuffe *et al.*, 2011).

I hypothesize that LPL and LDL receptor will be downregulated in mouse placentas. This hypothesis is based on findings of reduced placental LPL activity in hydrocortisone treated term placental explants (Mateos *et al.*, 2018) and reduced LDL receptor expression in placentas from IUGR pregnancies (Wadsack *et al.*, 2007).

## **Aim 1.3:** Is placental mTORC1 signaling altered after maternal GC exposure?

I hypothesize that placental mTORC1 activity will be reduced in placentas exposed to dexamethasone. This is because mice exposed to corticosterone at E14-E19 had reduced expression of downstream targets of mTORC1 and increased expression of REDD1, an inhibitor of mTORC1 signaling (Vaughan *et al.*, 2015). Furthermore, the expected IUGR (from *Aim 1*) may be supportive of reduced mTORC1 signaling.

## **Aim 1.4:** How does maternal GC exposure affect placental endocrine function?

I hypothesize GDF15, an anorexic hormone, to be downregulated in the placentas of dexamethasone-treated animals. Given that GDF15 levels are increased in muscle with activated mTORC1 activity (Tang *et al.*, 2019; Stephenson *et al.*, 2019) and reduced in plasma after rapamycin treatment (Khan *et al.*, 2017), and since placental mTORC1 activity is predicted to be reduced (from *Aim 3*), then GDF15 levels should decrease accordingly.

I expect IGF2 expression to be reduced since pregnant rats treated with dexamethasone at E13 had reduced *Igf2* mRNA expression in the junctional zone despite unaltered expression in the labyrinth zone (Ain *et al.*, 2005). Since our exposure is more chronic and placental weight and development is expected to be reduced (from *Aim 1*), then placental *Igf2* should be reduced.

## **Aim 1.5:** Is offspring survival, weight, body composition and insulin sensitivity altered with maternal GC exposure?

Given the severe expected IUGR, reduced fetal weights, and increased resorption (from *Aim 1*), I predict that offspring survival will be reduced. Our preliminary data shows that pre-gestational exposure will dramatically reduce offspring survival at PND0.5-1 with 100% lethality of all pups from dexamethasone-treated dams. Dexamethasone exposure at conception is similarly predicted to reduce offspring survival within PND0.5-1 but to a lesser degree than the pre-gestational exposure. I predict offspring body weight to be relatively similar at 6 weeks as seen in adult rats (Lesage *et al.*, 2004; O’Sullivan *et al.*, 2013), but the offspring will have higher fat mass as seen in human studies (Van Dijk *et al.*, 2012). Furthermore, since our exposure is longer than that of most studies, offspring may show increased insulin levels during the ITT at 6 weeks of age. In support of this hypothesis, 30-year-old human offspring of mothers who had received antenatal betamethasone had higher insulin levels 30 minutes after a glucose tolerance test (Dalziel *et al.*, 2005). On the other hand, adult rat offspring of antenatally stressed dams had unaffected insulin secretion in response to an OGTT (Lesage *et al.*, 2004), but since our exposure is more chronic prior to or at gestation, then I expect insulin levels to be higher indicating less insulin sensitivity.

## **Aim 1.6:**Does a placental GR-KO model rescue the placental and fetal effects of GC exposure?

Based on the results of Aims 1.1-1.5 we will have identified critical glucocorticoid-induced changes in placental gene expression, signaling, placental and fetal size and offspring health. Those models however do not separate effects of dexamethasone on the mother from those on the placenta. To separate these we will use placental GR knockouts and repeat these studies. We expect that placental-derived glucocorticoid actions will be blocked by GR knockout in the placenta, but maternal glucocorticoid actions will be retained.

# Potential Pitfalls and Alternate Approaches (Aims 1.1-1.6)

It is possible that mice in the pre-gestation dexamethasone will not conceive immediately upon mating thus causing their 1 week dexamethasone exposure prior to mating to be prolonged. We will have to eliminate all dams that will be exposed to pre-gestational dexamethasone for more than a week and the half prior to conception, thus we may need more mice. It is also possible for both groups that the mice may have spontaneous abortions and resorptions due to induced dexamethasone-induced stress even prior to the E14.5 timepoint. We may thus need to alter our exposure time and try different exposure windows for shorter periods of time during gestation. It is also possible that our placental GR KO model may prove lethal. In that case, we will use a different parental strain of Hets (Het x Het) to generate a partial knockout that may prove viable.

# Appendix A: Summary Table of Compiled Studies Examining Effects of Antenatal GC on Placental/Fetal Development and Health

|  |  |  |
| --- | --- | --- |
| Paper | Methods/Exposure | Results |
| (Hahn *et al.*, 1999) | Human placental extracts from term pregnancy treated with triamcinolone (TA)  E21 Rat placentas from rats injected with 0.38mg/kg TA once at E16  Mouse E17 placentas from GR transgenic mice using antisense RNA – this antisense is in the mother, but in placenta GR protein expression was reduced by 28% | Human TB cells had GLUT1 on MVM, GLUT3 on endothelial cells  GLUT1 mRNA and protein reduced after TA  GLUT3 mRNA unaffected, but protein decreased  In rat and mouse, GLUT1 and GLUT3 localized in STB, CTB and endothelial cells(weakest in CTB)  In rats, fetal and placental weights reduced by 73% and 53%, respectively at E21.  Implantation number unaffected  GLUT1 and GLUT3 mRNA and protein reduced after TA  Placental wt of transgenic mice reduced by 28%, offspring of transgenic mice were 20% lighter  GLUT1 mRNA and protein was reduced  GLUT3 mRNA and protein increased |
| (Vaughan *et al.*, 2015) | 2 Mice cohorts given corticosterone in drinking water at two intervals:  1. E11-E16  2. E14-E19  The dose was designed to produce plasma cort levels that are high and similar to concentrations reported in heat/light stressed dams  Unidirectional materno-fetal clearance of non-metabolizable glucose was assessed | On D19, transplacental 3Hmethyl-D-glucose clearance decreased by 33%  Cort reduced fetal weight by 8% and 19% at D16 and D19, respectively  Placental weight was reduced at both points  Number of viable pups was unaffected  At D19, materno-fetal clearance and fetal accumulation of glucose tracer was lower than controls at E19. No difference in clearance or accumulation at D16  Placental *Slc2a1&3* (GLUT 1 and 3) mRNA expression increased at E16, no change in expression on E19  *Redd1* expression increased on D19 but not D16 with cort and was in sync with the reduced transplacental glucose transport at D19  No change in placental *Igf2* expression  On D16, pAkt was reduced 🡪 less active Akt |
| (Vaughan *et al.*, 2012) | 2 Mice cohorts given corticosterone in drinking water at two intervals:  1. E11-E16  2. E14-E19 | Fetal weight reduced in both  At D16, no effect on materno-fetal transfer of labeled amino acid  Fetal and placental weight reduced by 7% on D16  On D19, fetus weight decreased by 16% and placental weight was 11% smaller  Fetal weight negatively correlated with maternal corticosteroid levels at E19 but not E16  Number of viable pups per litter was unchanged with maternal cort  Fetal accumulation of MeAIB was not changed at E16, but placental accumulation was 35% more (expression of placental transporters was up as well, mentioned below)  At E19, placental and fetal MeAIB accumulation was reduced by 40-50%, after tx from E14-E19 (although placental transporter snat1 increased and others did not change)  Oppositely at E19, from dams treated E11-E16 (3 days post tx), fetal accumulation and clearance were 38% higher but placental accumulation was unchanged 🡪 longer term effects of GC tx after cessation of tx  At E16, *Slc38a1 and 2* expression in placenta was increased, *Slc38a4* was unchanged  At E19, *Slc38a1* expression increased, but no change in *Slc38a2 or 4*  Placentas weighed less at E16 but volume of zones did not differ. No difference in zone at E19  Reduced vascularity shown by less fetal capillaries in the labyrinthine zone by 55% at E16 |
| (Audette *et al.*, 2010) | Human placental explants from term-pregnancies in healthy women  Placental explants incubated with radiolabeled 14C-MeAIB for different periods  Dex added at 10-6 M | Dex treatment increased placental uptake of MeAIB at 10-6M but not at 10-8M 🡪 stimulated system A activity at 10-6M with 30% increase of MeAIB uptake  No change in mRNA expression of SNAT1,2 or 4 with Dex.  No effect on placental apoptosis |
| (Jones *et al.*, 2006) | BeWo choriocarcinoma cell line used with 14CMeAIB infusion to assess transport of system A aa  Cortisol was added to incubated cells at concentrations 5nM-2.5uM for up to 24 hours | BeWo cells incubated with 1000nM cortisol had higher MeAIB transfer from apical to basolateral chambers over 20 minutes  SNAT1 mRNA was unchanged with cortisol at multiple concentrations  SNAT2 mRNA levels increased by 21% at 24h incubation of 1uM cortisol. Cort exposure of 2.5uM for 24 hours increase SNAT2 mRNA expression by 30%  Protein expression of SNAT1 was not assessed  Protein expression of SNAT2 showed increased expression with 1uM of cortisol for 24 hours by 11% |
| (Audette *et al.*, 2011) | Pregnant mice treated with 0.1mg/kg dex injected at E13.5 and E14.5 (midgestation exposure)  Transfer studies done at E12.5, E15.5 (24hr after tx) , E17.5 (72h after tx) and E18.5 (96h after tx)  Subset of dams were allowed to deliver their pups | In saline injected controls, placental and fetal weights increased from E12.5 to E15.5 to E18.5. Placental 14CMeAIB transfer also increased which was consistent with increases in system A gene expression of SNAT1, 2 and 4 as pregnancy progressed.  Effects of Dex: Treatment from E13.5 and E14.5 did not alter 14CMeAIB transfer at E15.5 or E17.5, but transfer was reduced at E18.5 in male and female placentas (long-term after treatment cessation).  SNAT1,2 and 4 mRNA expression was unchanged with Dex in male and female placentas at E15.5, 17.5 and 18.5 (despite reduced transfer at E18.5)  Fetal weights at E15.5, E18.5 or at birth was unchanged.  No change on placental weight at E15.5, E17.5 and E18.5 in males. In females there was no change at E15.5 or E17.5, but placental weight was reduced at E18.5 🡪 the reduced female placental weight at E18.5 increased the fetal:placental ratio at E18.5  No change in placental labyrinth or junctional zone proportions w.r.t. total placental area  No difference in maternal or fetal plasma corticosterone concentrations at E18.5 |
| (Cuffe *et al.*, 2011) | Pregnant mice treated with Dex 1ug/kg/h minipump for 60 hours (2.5 days) via a minipump starting at E12.5  Placentas collected at E14.5 (2 days- 48 hours) and at E17.5 (after 5 days of initial exposure, after 2.5 days from end of exposure) | Reduced fetal body weight at E14.5 in males and females, but not at E17.5.  Reduced female placental weight at E14.5 but not E17.5. Male placental weight was unchanged in both days.  *Igf2* expression not affected by Dex at either age.  GLUT1, GLUT3, SNAT 1, SNAT2 and SNAT4 gene expression was unaltered after Dex at E14.5 and E17.5  No differences in placental areas or gross morphology  Female junctional zone cross sectional area was smaller at E14.5.  Whole placental cross sectional area was smaller. |
| (Audette *et al.*, 2014) | Used placental extracts from pregnancies treated with GC who delivered at various times during gestation.  Women recruited if they received 2 doses of celestone (betamethasone 12 mg intramuscular ~12 hours apart) at 23.6 and 33.9 weeks of gestation  Groups:  1. mom who delivered preterm 24h-14 days after tx  2. who delivered 14d-after treatment but still delivered before term  3.who received GC but delivered at term | Fetuses born 24hours-14 days after the GC treatment (preterm delivery) had reduced birth weight compared to fetuses born 14days post treatment until term (term pregnancies).  No difference between birth weight of GC treated fetuses at term and term controls (not treated with GC)  Placentas of fetuses delivered between 24h-14d after the tx had significantly lower weights compared to placentas from 14d-term deliveries with GC.  Uptake of 14CMeAIB by placental explants from GC treated moms who delivered 14d-term or at term after the treatment had reduced system A activity compared to placentas from preterm delivery.  Placentas from preterm delivery (24h-14d post GC) had no change in MeAIB uptake compared to control term placentas  Placentas of GC treated moms who delivered at term had significantly reduced system A transport compared to control term placentas.  Expression of placental AA transporters:  No effect of SNAT 1 or SNAT2  SNAT4 gene expression was reduced in placentas of GC treated moms at term compared to GC treated placentas of fetuses born 14d-term after GC treatment |
| (Mateos *et al.*, 2018) | Placentas obtained from healthy women who delivered at term. Placental explants cultured with or without GC hydrocortisone 1mg/ml (2.75 mM) | Placentas incubated with 1mg/ml hydrocortisone had unchanged 3H-2DOG uptake, but higher concentrations of 2mg/ml and 20mg/ml showed reduced DOG uptake by 30-40%  Expression of GLUT1 was not changed with all concentrations  GLUT3 mRNA expression was increased with 2mg/ml incubation only  GLUT1 protein expression was increased at 1mg/ml, 2mg/ml and 20mg/ml of hydrocortisone  Fatty acid oxidation was reduced by 25%, 50% and 75% in explants treated with 1, 2 and 20 mg/ml, respectively  Fatty acid esterification (to make TG or to undergo oxidation) was also reduced at all concentrations, consistent with the fact that there was less oxidation.  Lipoprotein lipase activity was reduced significantly by 40% and 80% at 2 and 20 mg/ml doses, respectively (LPL is needed to allow uptake of fatty acids that will then become esterified and undergo oxidation or become TG)  Mitochondrial activity in placental explants was significantly reduced at 20mg/ml only, but TUNEL analysis showed no differences in apoptosis  Hence, glucose and lipid uptake were reduced in placentas despite available nutrients |
| (Baisden *et al.*, 2007) | Pregnant mice injected with 0.5mg/kg intraperitoneal dexamethasone on E15, E16 and E17 to mimic multiple course of antenatal GC treatment | At E20, dex placentas were pale and weighed less.  Dex treatment was not associated with fetal death.  Trophoblasts in labyrinth and junctional zones were swollen with loss of TB in junctional zone (marked by empty space in H&E stain)  Downregulation of 1212 genes and up-regulation of 1382 genes 🡪 decreased expression of genes involved in cell division with mixed responses on genes regulating glucose, cholesterol and steroid metabolism  No difference in gene expression of *Igf1 or 2* |
| (Braun *et al.*, 2013) | Mothers who received a single course of betamethasone treatment during pregnancy  Single course is 2 x 12 mg betamethasone in 2 consecutive days given intramuscularly  Collected maternal plasma at 4 timepoints:  1.prior to first GC administration  2. 24 hours after first GC administration and right before the second dose of 12mg betamethasone  3. 48 hours after the first GC tx (24h after second dose)  4. Finally, one sample collected during delivery at 4-5cm cervical dilation | Single Betamethasone treatment was associated with reduced fetal growth and reduced head circumference.  Birth weight was reduced by 18.2% after betamethasone.  Placental width was reduced by 5.5% with insignificant but reduced surface area by 14.7%  Birth weight was positively associated with placental surface area.  Betamethasone increased STB cell circumference and cell surface. |
| (Langdown & Sugden, 2001) | Pregnant rats given dexamethasone by subcutaneous infusion at E15 via a pump at a dose of 100 or 200 ug/kg body wt/day  Sac at E21 | Reduced fetal and placental weights that was dose-dependent, the 200 dex dose had a larger impact on weight reduction  No effect of dex on gestation length or offspring number or viability  Maternal blood showed higher but insignificant blood glucose when dex treated at 200 dose.  Fetal hypoglycemia was evident and showed 36% and 49% reduction in fetal plasma glucose at 100 and 200 ug dex, respectively.  Increase in placental GLUT1 protein expression by 1.6 and 1.9 fold at 100 and 200 ug/kg/day dex doses, respectively.  Increased GLUT3 protein expression by 2.3 fold only with the 200 ug dex dose. |
| (Dupouy *et al.*, 1987) | Dex treated rats at E15 till E21 with dexamethasone acetate in drinking water at 10ug/ml dose | 21 day old rats offspring from stressed dams showed reduced headless body weight (- 66%)  Lower offspring hypothalamic Corticotropin releasing factor content and concentration from 21-day old rats of stressed dams (-57 and -67%, respectively )  Lower pituitary ACTH content (-93 %) and lower plasma ACTH levels.  Lower adrenal corticosterone concentrations (-74%) and lower plasma corticosterone levels.  Severe atrophy of adrenals with reduced absolute adrenal weight (- 83%) and reduced relative adrenal to body weight |
| (Ain *et al.*, 2005) | Rats injected subcutaneously with 100ug dexamethasone acetate in 0.1% ethanol at E13.  Pump was then implanted to release 200ug dex acetate/kg body wt/day  Sac on E20 | Dex did not affect litter size or fetal viability.  Significant reduction of fetal and placental weights.  Decrease of junctional zone. *Igf2* mRNA expression but no effect on it in labyrinth zone 🡪 can be a contributor to placental growth restriction  Decrease protein expression of phosphorylated/active Akt, but no effect on total Akt 🡪 attenuated Akt signaling |
| (Lesage *et al.*, 2004) | Rats exposed to stress by being in a plastic cylinder in a lighted environment 3x/day for 45 minutes each during last week of gestation.  Sac at E20 | Fetuses of stressed dams had reduced body weights in males and females 🡪 IUGR  Fetal plasma glucose and corticosterone levels were reduced but leptin was unchanged.  Effect of antenatal stress on offspring:  24-month old male rats had unchanged weights after antenatal exposure of stress  Basal plasma corticosterone levels were higher but not significant  Plasma leptin was reduced  OGTT showed higher plasma glucose levels in antenatally stressed rats at all timepoints (0, 60 and 120 minutes tested), but insulin secretion was similar. |

Ain R, Canham LN & Soares MJ (2005). Dexamethasone-induced intrauterine growth restriction impacts the placental prolactin family, insulin-like growth factor-II and the Akt signaling pathway. *J Endocrinol* **185,** 253–263.

Alexander N, Rosenlöcher F, Stalder T, Linke J, Distler W, Morgner J & Kirschbaum C (2012). Impact of Antenatal Synthetic Glucocorticoid Exposure on Endocrine Stress Reactivity in Term-Born Children. *J Clin Endocrinol Metab* **97,** 3538–3544.

Andrade SE, Gurwitz JH, Davis RL, Chan KA, Finkelstein JA, Fortman K, Mcphillips H, Raebel MA, Roblin D, Smith DH, Yood MU, Morse AN & Platt R (2004). Prescription drug use in pregnancy. *Am J Obstet Gynecol* **191,** 398–407.

Audette MC, Challis JRG, Jones RL, Sibley CP & Matthews SG (2011). Antenatal Dexamethasone Treatment in Midgestation Reduces System A-Mediated Transport in the Late-Gestation Murine Placenta. ; DOI: 10.1210/en.2011-0104.

Audette MC, Challis JRG, Jones RL, Sibley CP & Matthews SG (2014). Synthetic Glucocorticoid Reduces Human Placental System A Transport in Women Treated With Antenatal Therapy. *J Clin Endocrinol Metab* **99,** E2226–E2233.

Audette MC, Greenwood SL, Sibley CP, Jones CJP, Challis JRG, Matthews SG & Jones RL (2010). Dexamethasone stimulates placental system A transport and trophoblast differentiation in term villous explants. *Placenta* **31,** 97–105.

Baisden B, Sonne S, Joshi RM, Ganapathy V & Shekhawat PS (2007). Antenatal dexamethasone treatment leads to changes in gene expression in a murine late placenta. *Placenta* **28,** 1082–1090.

Bakker JM, Schmidt ED, Kroes H, Kavelaars A, Heijnen CJ, Tilders FJH & van Rees EP (1995). Effects of short-term dexamethasone treatment during pregnancy on the development of the immune system and the hypothalamo-pituitary adrenal axis in the rat. *J Neuroimmunol* **63,** 183–191.

Barker DJP (2007). The origins of the developmental origins theory. *J Intern Med* **261,** 412–417.

Barlow SM, Morrison PJ & Sullivan FM (1973). Plasma corticosterone levels during pregnancy in the mouse. *Br J Pharmacol* **48,** 346P.

Bayliss RIS, Browne JCM, Round B & Steinbeck AW (1955). PLASMA-17-HYDROXYCORTICOSTEROIDS IN PREGNANCY. *Lancet* **265,** 62–64.

Braun T, Challis JR, Newnham JP & Sloboda DM (2013). Early-Life Glucocorticoid Exposure: The Hypothalamic-Pituitary-Adrenal Axis, Placental Function, and Long-term Disease Risk. *Endocr Rev* **34,** 885–916.

Brett K, Ferraro Z, Yockell-Lelievre J, Gruslin A & Adamo K (2014). Maternal–Fetal Nutrient Transport in Pregnancy Pathologies: The Role of the Placenta. *Int J Mol Sci* **15,** 16153–16185.

Bronson SL & Bale TL (2016). The Placenta as a Mediator of Stress Effects on Neurodevelopmental Reprogramming. *Neuropsychopharmacology* **41,** 207–218.

Buss C, Davis EP, Shahbaba B, Pruessner JC, Head K & Sandman CA (2012). Maternal cortisol over the course of pregnancy and subsequent child amygdala and hippocampus volumes and affective problems. *Proc Natl Acad Sci U S A* **109,** E1312-9.

Carr BR, Parker CR, Madden JD, MacDonald PC & Porter JC (1981). Maternal plasma adrenocorticotropin and cortisol relationships throughout human pregnancy. *Am J Obstet Gynecol* **139,** 416–422.

Cetin I, Ronzoni S, Marconi AM, Perugino G, Corbetta C, Battaglia FC & Pardi G (1996). Maternal concentrations and fetal-maternal concentration differences of plasma amino acids in normal and intrauterine growth-restricted pregnancies. *Am J Obstet Gynecol* **174,** 1575–1583.

Chen Q, Wang Y, Zhao M, Hyett J, da Silva Costa F & Nie G (2016). Serum levels of GDF15 are reduced in preeclampsia and the reduction is more profound in late-onset than early-onset cases. *Cytokine* **83,** 226–230.

Cuffe JSM, Dickinson H, Simmons DG & Moritz KM (2011). Sex specific changes in placental growth and MAPK following short term maternal dexamethasone exposure in the mouse. *Placenta* **32,** 981–989.

Dalziel SR, Walker NK, Parag V, Mantell C, Rea HH, Rodgers A & Harding JE (2005). Cardiovascular risk factors after antenatal exposure to betamethasone: 30-year follow-up of a randomised controlled trial. *Lancet* **365,** 1856–1862.

Davis EP, Townsend EL, Gunnar MR, Georgieff MK, Guiang SF, Ciffuentes RF & Lussky RC (2004). Effects of prenatal betamethasone exposure on regulation of stress physiology in healthy premature infants. *Psychoneuroendocrinology* **29,** 1028–1036.

Van Dijk AE, Van Eijsden M, Stronks K, Gemke RJBJ & Vrijkotte TGM (2012). The relation of maternal job strain and cortisol levels during early pregnancy with body composition later in the 5-year-old child: The ABCD study. *Early Hum Dev* **88,** 351–356.

Doyle LW, Ford GW, Rickards AL, Kelly EA, Davis NM, Callanan C & Olinsky A (2000). Antenatal corticosteroids and outcome at 14 years of age in children with birth weight less than 1501 grams. *Pediatrics* **106,** E2.

Dupouy J-P, Chatelain A, Boudouresque F, Conte-Devolx B & Oliver C (1987). Effects of Chronic Maternal Dexamethasone Treatment on the Hormones of the Hypothalamo-Pituitary-Adrenal Axis in the Rat Fetus. *Neonatology* **52,** 216–222.

Duthie L & Reynolds RM (2013). Changes in the maternal hypothalamic-pituitary-adrenal axis in pregnancy and postpartum: influences on maternal and fetal outcomes. *Neuroendocrinology* **98,** 106–115.

Entringer S, Buss C, Rasmussen JM, Lindsay K, Gillen DL, Cooper DM & Wadhwa PD (2016). Maternal cortisol during pregnancy and infant adiposity: a prospective investigation. *J Clin Endocrinol Metab* **102,** jc.2016-3025.

Gaccioli F, Aye ILMH, Roos S, Lager S, Ramirez VI, Kanai Y, Powell TL & Jansson T (2015). Expression and functional characterisation of System L amino acid transporters in the human term placenta. *Reprod Biol Endocrinol* **13,** 57.

Georgiades P, Ferguson-Smith AC & Burton GJ (2002). Comparative Developmental Anatomy of the Murine and Human Definitive Placentae. *Placenta* **23,** 3–19.

Glazier JD, Cetin I, Perugino G, Ronzoni S, Grey AM, Mahendran D, Marconi AM, Pardi G & Sibley CP (1997). Association between the Activity of the System A Amino Acid Transporter in the Microvillous Plasma Membrane of the Human Placenta and Severity of Fetal Compromise in Intrauterine Growth Restriction. *Pediatr Res* **42,** 514–519.

Hahn T, Barth S, Graf R, Engelmann M, Beslagic D, Reul JMHM, Holsboer F, Dohr G & Desoye G (1999). Placental Glucose Transporter Expression Is Regulated by Glucocorticoids 1. *J Clin Endocrinol Metab* **84,** 1445–1452.

Hahn T & Desoye G (1996). Ontogeny of glucose transport systems in the placenta and its progenitor tissues. *Early Pregnancy* **2,** 168–182.

Hochberg I, Tran QT, Barkan AL, Saltiel AR, Chandler WF & Bridges D (2015). Gene Expression Signature in Adipose Tissue of Acromegaly Patients. *PLoS One* **10,** e0129359.

Huter O, Wolf HJ, Schnetzer A & Pfaller K (1997). Lipoprotein lipase, LDL receptors and apo-lipoproteins in human fetal membranes at term. *Placenta* **18,** 707–715.

Hviid A & Mølgaard-Nielsen D (2011). Corticosteroid use during pregnancy and risk of orofacial clefts. *CMAJ* **183,** 796–804.

Inder WJ, Prickett TCR, Ellis MJ, Hull L, Reid R, Benny PS, Livesey JH & Donald RA (2001). The Utility of Plasma CRH as a Predictor of Preterm Delivery. *J Clin Endocrinol Metab* **86,** 5706–5710.

Jafari Z, Mehla J, Afrashteh N, Kolb BE & Mohajerani MH (2017). Corticosterone response to gestational stress and postpartum memory function in mice ed. Pawluski J. *PLoS One* **12,** e0180306.

Jansson T & Powell TL (2013). Role of placental nutrient sensing in developmental programming. *Clin Obstet Gynecol* **56,** 591–601.

Jansson T, Scholtbach V & Powell TL (1998). Placental Transport of Leucine and Lysine Is Reduced in Intrauterine Growth Restriction1. *Pediatr Res* **44,** 532–537.

Jones HN, Ashworth CJ, Page KR & McArdle HJ (2006). Cortisol stimulates system A amino acid transport and SNAT2 expression in a human placental cell line (BeWo). *Am J Physiol Metab* **291,** E596–E603.

Jung C, Ho JT, Torpy DJ, Rogers A, Doogue M, Lewis JG, Czajko RJ & Inder WJ (2011). A Longitudinal Study of Plasma and Urinary Cortisol in Pregnancy and Postpartum. *J Clin Endocrinol Metab* **96,** 1533–1540.

Kemp MW, Newnham JP, Challis JG, Jobe AH & Stock SJ (2015). The clinical use of corticosteroids in pregnancy. *Hum Reprod Update* **22,** dmv047.

Khan NA, Nikkanen J, Yatsuga S, Jackson C, Wang L, Pradhan S, Kivelä R, Pessia A, Velagapudi V & Suomalainen A (2017). mTORC1 Regulates Mitochondrial Integrated Stress Response and Mitochondrial Myopathy Progression. *Cell Metab* **26,** 419-428.e5.

Kipmen-Korgun D, Ozmen A, Unek G, Simsek M, Demir R & Korgun ET (2012). Triamcinolone up-regulates GLUT 1 and GLUT 3 expression in cultured human placental endothelial cells. *Cell Biochem Funct* **30,** 47–53.

Langdown ML & Sugden MC (2001). Enhanced placental GLUT1 and GLUT3 expression in dexamethasone-induced fetal growth retardation. *Mol Cell Endocrinol* **185,** 109–117.

Lesage J, Del-Favero F, Leonhardt M, Louvart H, Maccari S, Vieau D & Darnaudery M (2004). Prenatal stress induces intrauterine growth restriction and programmes glucose intolerance and feeding behaviour disturbances in the aged rat. *J Endocrinol* **181,** 291–296.

Lindsay JR & Nieman LK (2005). The Hypothalamic-Pituitary-Adrenal Axis in Pregnancy: Challenges in Disease Detection and Treatment. *Endocr Rev* **26,** 775–799.

Lu B, Bridges D, Yang Y, Fisher K, Cheng A, Chang L, Meng Z-X, Lin JD, Downes M, Yu RT, Liddle C, Evans RM & Saltiel AR (2014). Metabolic Crosstalk: Molecular Links Between Glycogen and Lipid Metabolism in Obesity. *Diabetes* **63,** 2935–2948.

Lunghi L, Pavan B, Biondi C, Paolillo R, Valerio A, Vesce F & Patella A (2010). Use of Glucocorticoids in Pregnancy. *Curr Pharm Des* **16,** 3616–3637.

Magnusson AL, Waterman IJ, Wennergren M, Jansson T & Powell TL (2004). Triglyceride Hydrolase Activities and Expression of Fatty Acid Binding Proteins in the Human Placenta in Pregnancies Complicated by Intrauterine Growth Restriction and Diabetes. *J Clin Endocrinol Metab* **89,** 4607–4614.

Malassine A, Frendo J-L & Evain-Brion D (2003). A comparison of placental development and endocrine functions between the human and mouse model. *Hum Reprod Update* **9,** 531–539.

Mateos RM, Jiménez G, Álvarez-Gil C, Visiedo F, Rivera-Rodríguez F, Santos-Rosendo C, Rodriguez-Pareja A, Perdomo G & Lechuga-Sancho AM (2018). Excess Hydrocortisone Hampers Placental Nutrient Uptake Disrupting Cellular Metabolism. *Biomed Res Int* **2018,** 1–11.

Moisiadis VG & Matthews SG (2014). Glucocorticoids and fetal programming part 1: outcomes. *Nat Rev Endocrinol* **10,** 391–402.

Mparmpakas D, Zachariades E, Goumenou A, Gidron Y & Karteris E (2012). Placental DEPTOR as a stress sensor during pregnancy. *Clin Sci (Lond)* **122,** 349–359.

Napso T, Yong HEJ, Lopez-Tello J & Sferruzzi-Perri AN (2018). The Role of Placental Hormones in Mediating Maternal Adaptations to Support Pregnancy and Lactation. *Front Physiol* **9,** 1091.

Ng PC (2000). The fetal and neonatal hypothalamic-pituitary-adrenal axis. *Arch Dis Child Fetal Neonatal Ed* **82,** F250-4.

Norberg S, Powell TL & Jansson T (1998). Intrauterine Growth Restriction Is Associated with a Reduced Activity of Placental Taurine Transporters. *Pediatr Res* **44,** 233–238.

O’Sullivan L, Cuffe JSM, Paravicini TM, Campbell S, Dickinson H, Singh RR, Gezmish O, Black MJ & Moritz KM (2013). Prenatal exposure to dexamethasone in the mouse alters cardiac growth patterns and increases pulse pressure in aged male offspring. *PLoS One* **8,** e69149.

Ochsner S et al. (2019). The Signaling Pathways Project: an integrated ‘omics knowledgebase for mammalian cellular signaling pathways. *bioRxiv*401729.

Padoan A, Rigano S, Ferrazzi E, Beaty BL, Battaglia FC & Galan HL (2004). Differences in fat and lean mass proportions in normal and growth-restricted fetuses. *Am J Obstet Gynecol* **191,** 1459–1464.

Petry CJ, Ong KK, Burling KA, Barker P, Goodburn SF, Perry JRB, Acerini CL, Hughes IA, Painter RC, Afink GB, Dunger DB & O’Rahilly S (2018). Associations of vomiting and antiemetic use in pregnancy with levels of circulating GDF15 early in the second trimester: A nested case-control study. *Wellcome open Res* **3,** 123.

Ponnusamy S, Tran QT, Harvey I, Smallwood HS, Thiyagarajan T, Banerjee S, Johnson DL, Dalton JT, Sullivan RD, Miller DD, Bridges D & Narayanan R (2017). Pharmacologic activation of estrogen receptor β increases mitochondrial function, energy expenditure, and brown adipose tissue. *FASEB J* **31,** 266–281.

Regnault TRH, Orbus RJ, de Vrijer B, Davidsen ML, Galan HL, Wilkening RB & Anthony RV (2002). Placental Expression of VEGF, PlGF and their Receptors in a Model of Placental Insufficiency—Intrauterine Growth Restriction (PI-IUGR). *Placenta* **23,** 132–144.

Reynolds RM (2013). Glucocorticoid excess and the developmental origins of disease: Two decades of testing the hypothesis – 2012 Curt Richter Award Winner. *Psychoneuroendocrinology* **38,** 1–11.

Roos S, Jansson N, Palmberg I, Säljö K, Powell TL & Jansson T (2007). Mammalian target of rapamycin in the human placenta regulates leucine transport and is down-regulated in restricted fetal growth. *J Physiol* **582,** 449–459.

Schmidt M, Enthoven L, van der Mark M, Levine S, de Kloet ER & Oitzl MS (2003). The postnatal development of the hypothalamic–pituitary–adrenal axis in the mouse. *Int J Dev Neurosci* **21,** 125–132.

Shibata E, Hubel CA, Powers RW, von Versen-Hoeynck F, Gammill H, Rajakumar A & Roberts JM (2008). Placental system A amino acid transport is reduced in pregnancies with small for gestational age (SGA) infants but not in preeclampsia with SGA infants. *Placenta* **29,** 879–882.

Singh RR, Cuffe JS & Moritz KM (2012). Short- and long-term effects of exposure to natural and synthetic glucocorticoids during development. *Clin Exp Pharmacol Physiol* **39,** 979–989.

Stephenson EJ, Redd JR, Snyder D, Tran QT, Lu B, Peloquin MJ, Mulcahy MC, Harvey I, Fisher K, Han JC, Qi N, Saltiel AR & Bridges D (2019). Skeletal Muscle mTORC1 Activation Increases Energy Expenditure and Reduces Longevity in Mice. *bioRxiv*720540.

Sugulle M, Dechend R, Herse F, Weedon-Fekjaer MS, Johnsen GM, Brosnihan KB, Anton L, Luft FC, Wollert KC, Kempf T & Staff AC (2009). Circulating and placental growth-differentiation factor 15 in preeclampsia and in pregnancy complicated by diabetes mellitus. *Hypertens (Dallas, Tex 1979)* **54,** 106–112.

Tang H et al. (2019). mTORC1 underlies age‐related muscle fiber damage and loss by inducing oxidative stress and catabolism. *Aging Cell* **18,** e12943.

Tong S, Marjono B, Brown DA, Mulvey S, Breit SN, Manuelpillai U & Wallace EM (2004). Serum concentrations of macrophage inhibitory cytokine 1 (MIC 1) as a predictor of miscarriage. *Lancet* **363,** 129–130.

Urraca N, Memon R, El-Iyachi I, Goorha S, Valdez C, Tran QT, Scroggs R, Miranda-Carboni GA, Donaldson M, Bridges D & Reiter LT (2015). Characterization of neurons from immortalized dental pulp stem cells for the study of neurogenetic disorders. *Stem Cell Res* **15,** 722–730.

Vaughan OR, Fisher HM, Dionelis KN, Jefferies EC, Higgins JS, Musial B, Sferruzzi-Perri AN & Fowden AL (2015). Corticosterone alters materno-fetal glucose partitioning and insulin signalling in pregnant mice. *J Physiol* **593,** 1307–1321.

Vaughan OR, Rosario FJ, Powell TL & Jansson T (2017). Regulation of Placental Amino Acid Transport and Fetal Growth. *Prog Mol Biol Transl Sci* **145,** 217–251.

Vaughan OR, Sferruzzi-Perri AN & Fowden AL (2012). Maternal corticosterone regulates nutrient allocation to fetal growth in mice. *J Physiol* **590,** 5529–5540.

Wadsack C, Tabano S, Maier A, Hiden U, Alvino G, Cozzi V, Hüttinger M, Schneider WJ, Lang U, Cetin I & Desoye G (2007). Intrauterine growth restriction is associated with alterations in placental lipoprotein receptors and maternal lipoprotein composition. *Am J Physiol Metab* **292,** E476–E484.

Waffarn F & Davis EP (2012). Effects of antenatal corticosteroids on the hypothalamic-pituitary-adrenocortical axis of the fetus and newborn: experimental findings and clinical considerations. *Am J Obstet Gynecol* **207,** 446–454.

Wen HY, Abbasi S, Kellems RE & Xia Y (2005). mTOR: A placental growth signaling sensor. *Placenta* **26,** S63–S69.

Wenzel PL & Leone G (2007). Expression of Cre recombinase in early diploid trophoblast cells of the mouse placenta. *genesis* **45,** 129–134.

Wieczorek A, Perani C V., Nixon M, Constancia M, Sandovici I, Zazara DE, Leone G, Zhang M-Z, Arck PC & Solano ME (2019). Sex-specific regulation of stress-induced fetal glucocorticoid surge by the mouse placenta. *Am J Physiol Metab* **317,** E109–E120.

Woods L, Perez-Garcia V & Hemberger M (2018). Regulation of Placental Development and Its Impact on Fetal Growth-New Insights From Mouse Models. *Front Endocrinol (Lausanne)* **9,** 570.

1. Powered to see 1.2SD effect size in placental and offspring weights, we need 10 female mice and 10 male mice per group (8 groups total) to get a power of 0.825. [↑](#footnote-ref-2)